Support program for women recovering from ovarian cancer
POSTCARE-O: Survivorship Care for Women Living With Ovarian Cancer
This study is testing a new online support program for women who have finished treatment for ovarian cancer to see if it improves their quality of life compared to standard care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Baylor College of Medicine Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 3 sites (Dallas, Texas and 2 other locations) |
| Trial ID | NCT05752448 on ClinicalTrials.gov |
What this trial studies
This study aims to enroll 120 women who have completed initial treatment for Stage 2-4 ovarian cancer to evaluate the effectiveness of a telehealth-delivered survivorship care process called POSTCare-O. Participants will be randomly assigned to receive either the POSTCare survivorship care or standard care, with the primary focus on assessing quality of life at 12 weeks post-intervention. The study will utilize both quantitative and qualitative methodologies to gather comprehensive data on the impact of the intervention. Outcomes will be measured at baseline, 12 weeks, and 24 weeks to provide insights into the survivorship transition experience.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 and older who have completed initial treatment for Stage 2-4 ovarian cancer within the last 6 months.
Not a fit: Patients who are admitted to hospice care at the completion of treatment will not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve the quality of life for women recovering from ovarian cancer.
How similar studies have performed: Other studies have shown promise in using telehealth for cancer survivorship care, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Stage 2-4 ovarian cancer * Treated with some combination of surgery, chemotherapy, biologics, maintenance therapy * Within 6 months of completion of initial treatment (continued maintenance therapy okay) * Able to provide consent in English or Spanish Exclusion Criteria: * Admission to hospice at the completion of treatment for ovary cancer
Where this trial is running
Dallas, Texas and 2 other locations
- UT Southwestern Parkland Health and Hospital System — Dallas, Texas, United States (Not_yet_recruiting)
- Dan L Duncan Comprehensive Cancer Center at the O'Quinn Medical Tower at Baylor St. Luke's Medical Center — Houston, Texas, United States (Recruiting)
- Harris Health Smith Clinic — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Elizabeth Kvale, MD,MPH — Baylor College of Medicine
- Study coordinator: Nimrah Saleem, MPH
- Email: nsaleem@bcm.edu
- Phone: 713-798-2272
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.